



EAPCI
European Association of
Percutaneous Cardiovascular
Interventions



ESC
European Society
of Cardiology

European Association of Percutaneous Cardiovascular Interventions

Your Name
Country :

**Application for the following position in the EAPCI Board 2024-2026:
PCR representative**

Current position

Head of the Department of Cardiology, University of Medical Sciences in Poznan

Profession

- Interventionalist**
- Healthcare Professional (Nurse, Radiographer, Technician) working in PCI
- Other (specify)

Additional Information

- Fellow of the ESC
- EAPCI Member
- Member of another ESC Association (beyond EAPCI)
*If yes, specify: **WG on Thrombosis***
- Active in an ESC Member Country
*If yes, specify your country of work: **Poland***
- Member of a National Cardiac Society
*If yes, specify: **Polish Cardiac Society***
- Member of an Interventional Working Group
*If yes, specify: **Association of CardioVascular Interventions (ACVI)***

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

Prof. Maciej Lesiak, MD, PhD, FESC

Nationality: Polish

Education

- physician, graduated with Honours
Karol Marcinkowski University of Medical Sciences, Poznań 1981 - 1987
- Scholarship of Ministry of Health for Outstanding Students, 1984

Qualifications

- Diploma of a Physician, 1987
- 1st Degree in Internal Medicine, 1990
- 2nd Degree in Internal Medicine, 1996
- Specialization in Cardiology, 2001

Academic Titles

- Doctor of Medicine (PhD), 1995
- Associate Professor of Medicine, 2007
- Professor of Medicine, 2012

Professional Experience

- 1st Department of Cardiology, Uniwersytecki Szpital Kliniczny w Poznaniu, Karol Marcinkowski University of Medical Sciences 1987 – present,
- Director, Catheterization Laboratory (1996 - 2017)
- Head of the Chair and 1st Department of Cardiology (2017 – Present)

Membership and Leadership Roles

- Polish Cardiac Society, Member since 1989
- European Society of Cardiology (ESC), Member since 2002, Fellow since 2016
- President, Association of Percutaneous Cardiovascular Interventions, Polish Cardiac Society, 2009 – 2011
- European Bifurcation Club, Member since 2005
- EuroPCR Program Committee Member since 2009
- Euro CTO Club, Full Member since 2019
- Euro 4C, Founding Member
- EAPCI Training & Education Committee member, 2010 – 2014
- EAPCI Scientific Programme & Congresses Committee, 2018 – 2020
- EAPCI Quality Improvement Committee, Co-chairman, 2020 - 2022
- EAPCI Quality Improvement Committee, Chairman, 2022 - 2024

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

Publications

- Authored over 350 papers in peer-reviewed medical journals.

Other Contributions

- ESC Guidelines Taskforce Member for 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
- Faculty and live case operator at major Interventional Cardiology meetings and workshops of the Polish Cardiac Society since 1998
- Faculty at ESC Congress, EuroPCR, and Transcatheter Cardiovascular Therapeutics (TCT)

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

Previous experience in EAPCI, ESC or your National Bodies

Specifically, please indicate if you hold an Executive position (President, Vice President, President Elect) in a National Cardiac Society or in the ESC. If so, please indicate which one as well as the term of this position.

- President, Association of Percutaneous Cardiovascular Interventions, Polish Cardiac Society, 2009 – 2011
- EAPCI Training & Education Committee member, 2010 – 2014
- EAPCI Scientific Programme & Congresses Committee, 2018 – 2020
- EAPCI Quality Improvement Committee, Co-chairman, 2020 - 2022
- EAPCI Quality Improvement Committee, Chairman, 2022 - 2024

If you have been involved in EAPCI in the past, please specify the position(s) as well as the relevant date(s)

In particular, please indicate if you served in:

- | | | |
|---|-----|------------------|
| • EAPCI Board 2022-2024 (under E. Barbato's leadership)? | Yes | <u>No</u> |
| • EAPCI Board 2020-2022 (under D. Dudek's leadership)? | Yes | <u>No</u> |
| • EAPCI Board 2018-2020 (under A. Baumbach's leadership)? | Yes | <u>No</u> |
| • EAPCI Board 2016-2018 (under M. Haude's leadership)? | Yes | <u>No</u> |

If you answered yes to at least one of these questions, please provide details.

- EAPCI Training & Education Committee member, 2010 – 2014
- EAPCI Scientific Programme & Congresses Committee, 2018 – 2020
- EAPCI Quality Improvement Committee, Co-chairman, 2020 - 2022
- EAPCI Quality Improvement Committee, Chairman, 2022 - 2024

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

Publications in the field of PCI (most important 10 publications)

Grajek S, Popiel M, Gil L, Breborowicz P, Lesiak M, et al. Influence of bone marrow stem cells on left ventricle perfusion and ejection fraction in patients with acute myocardial infarction of anterior wall: randomized clinical trial: Impact of bone marrow stem cell intracoronary infusion on improvement of microcirculation. *Eur Heart J*. 2010 Mar;31(6):691-702

Généreux P, Kumsars I, Lesiak M, Kini A, Fontos G, et al. A randomized trial of a dedicated bifurcation stent versus provisional stenting in the treatment of coronary bifurcation lesions. *J Am Coll Cardiol*. 2015 Feb 17;65(6):533-43.

Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. *EuroIntervention*. 2015 Feb;10(10):1144-53

Lesiak M, Łanocha M, Araszkiwicz A, Siniawski A, Grygier M, et al. Percutaneous coronary intervention for chronic total occlusion of the coronary artery with the implantation of bioresorbable everolimus-eluting scaffolds. Poznan CTO-Absorb Pilot Registry. *EuroIntervention*. 2016 Jun 12;12(2):e144-51.

Lesiak M, Araszkiwicz A, Grajek S, Colombo A, Lalmand J, et al. Long Coronary Lesions Treated With Thin Strut Bioresorbable Polymer Drug Eluting Stent: Experience From Multicentre Randomized CENTURY II Study. *J Interv Cardiol*. 2016 Feb;29(1):47-56.

Escaned J, Collet C, Ryan N, De Maria GL, Walsh S, Sabate M, Davies J, Lesiak M, et al. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. *Eur Heart J*. 2017 Nov 7;38(42):3124-3134.

Valgimigli M, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stanković G, Iñiguez A, Schultz C, Kornowski R, Ong PJJ, Alasnag M, Rodriguez AE, Moschovitis A, Laanmets P, Donahue M, Leonardi S, Smits PC; MASTER DAPT Investigators. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. *N Engl J Med*. 2021 Oct 28;385(18):1643-1655.

Smits PC, Frigoli E, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stankovic G, Iñiguez A, Schultz C, Kornowski R, Ong PJJ, Alasnag M, Rodriguez AE, Paradies V, Kala P, Kedev S, Al Mafragi A, Dewilde W, Heg D, Valgimigli M; MASTER DAPT Investigators. Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk. *J Am Coll Cardiol*. 2022 Sep 27;80(13):1220-1237.

Banning AP, Serruys P, De Maria GL, Ryan N, Walsh S, Gonzalo N, Jan van Geuns R, Onuma Y, Sabate M, Davies J, Lesiak M, et al. Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study. *Eur Heart J*. 2022 Mar 31;43(13):1307-1316.

Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, Espinola-Klein C, Fauchier L, Halle M, Herrington WG, Kautzky-Willer A, Lambrinou E, Lesiak M, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. *Eur Heart J*. 2023 Oct 14;44(39):4043-4140.

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

What would you like to achieve if you were elected? Please provide your 3 main topics (max 500 words)

Serving as the representative of EuroPCR within the European Association of Percutaneous Cardiovascular Interventions represents a confluence of scientific and organizational rigor and educational excellence. In this capacity, I am committed to harnessing EAPCI's substantial scientific and managerial capabilities to promote the dissemination of high-caliber training products, adhering to the highest standards. Concurrently, my ambition is for PCR to emerge as a pivotal instrument in reinforcing EAPCI's leadership in establishing best practices in clinical cardiology on a global scale.

Here are the three cornerstone goals I plan to pursue:

1. Fostering Collaborative Research and Innovation

I aim to support joint research initiatives between EAPCI and PCR, focusing on groundbreaking techniques and technologies in percutaneous cardiovascular and structural interventions. The synergy between these two esteemed organizations provides an unparalleled opportunity to advance our clinical capabilities and improve patient outcomes. By promoting a mature research collaboration with industry partners, I am committed to accelerating the translation of groundbreaking discoveries into practical clinical applications.

2. Expanding Educational Opportunities and Resources

Education lies at the heart of both EAPCI's and PCR's missions. In my role, I plan to enrich and expand the educational landscape for cardiologists by harnessing both organizations' collective expertise, networks, and resources. This will involve co-creating comprehensive training programs, workshops, and digital learning platforms tailored to the needs of today's interventional cardiologists. I aim to provide our community access to cutting-edge knowledge and practices, ensuring that cardiologists worldwide have the skills and insights necessary to deliver the highest quality of care.

3. Promoting International Standards and Best Practices

I am passionate about working towards harmonizing clinical standards and best practices in interventional cardiology across the globe. I intend to advocate for the widespread adoption of guidelines and protocols that EAPCI and PCR collaboratively develop. Establishing and promoting these international standards ensures consistency and excellence in patient care, regardless of geographic location. Through this effort, I aim to contribute to a global improvement in the quality and safety of cardiovascular interventions. My vision is to harness the collaborative potential of these organizations to advance research, education, and clinical practice, shaping a future where every patient receives the best possible cardiovascular care.

Besides, I would like to promote diversity and inclusivity within the interventional cardiology community actively. This encompasses efforts to support the career development of underrepresented groups in cardiology, including women and minorities, and to foster an inclusive environment at all levels of professional involvement.

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

If you were elected, how do you envisage to organize yourself to accommodate this very time demanding additional commitment?

Should I be honored with the election, I am fully prepared to embrace the additional responsibilities that come with my post. Thanks to my extensive experience in managing high-stakes roles and commitments, as the current head of the department of cardiology, I have honed my skills in strategic planning, prioritizing tasks, and delegating duties effectively to ensure operational excellence. I plan to apply these same principles to accommodate this new role.

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.